12:00 AM
 | 
Dec 08, 2003
 |  BioCentury  |  Strategy

Glaxo's Mini-Me future

GlaxoSmithKline plc says its burgeoning clinical pipeline is proof that its efforts to remake itself as a biotech mammal are more productive than remaining a pharma dinosaur.

Last week, the company said it has 30 more NCEs in the pipeline than it did in October 2001, and has increased the number of NCEs in Phase II and III from 23 to 44 in the same period. Perhaps most importantly, the number of compounds entering the clinic has increased from 28 to 49. And GSK (London, U.K.) expects to bring more than 20 NCEs into Phase III development over the next three years, and to make 16 "significant product" filings in the next two years.

Read the full 559 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >